Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
April 27, 2017
Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells
Monday O Ogese, Lee Faulkner, Roz E Jenkins, et al.
Journal of Medicinal Chemistry
|
February 25, 2016
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites
Michael H L Wong, Holly K Bryan, Ian M Copple, et al.
Redox Biology
|
October 18, 2025
Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases
Monika Jakubowska, Vera Marisa Costa, Wojciech Krzeptowski, et al.
Molecular Medicine (Cambridge, Mass.)
|
June 7, 2012
Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials
Ian M Copple, Amy E Mercer, James Firman, et al.
Scientific Reports
|
April 6, 2018
NRF2 regulates the glutamine transporter Slc38a3 (SNAT3) in kidney in response to metabolic acidosis
Adam Lister, Soline Bourgeois, Pedro H Imenez Silva, et al.
Kidney International
|
October 1, 2015
Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney
Luke M Shelton, Adam Lister, Joanne Walsh, et al.
Redox Biology
|
April 21, 2024
Biomarkers of NRF2 signalling: Current status and future challenges
Christina Morgenstern, Isabel Lastres-Becker, Birsen Can Demirdöğen, et al.
Oncotarget
|
June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget
|
February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Archives of Toxicology
|
November 15, 2018
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury
Ian M Copple, Wouter den Hollander, Giulia Callegaro, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
April 27, 2017
Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells
Monday O Ogese, Lee Faulkner, Roz E Jenkins, et al.
Journal of Medicinal Chemistry
|
February 25, 2016
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites
Michael H L Wong, Holly K Bryan, Ian M Copple, et al.
Redox Biology
|
October 18, 2025
Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases
Monika Jakubowska, Vera Marisa Costa, Wojciech Krzeptowski, et al.
Molecular Medicine (Cambridge, Mass.)
|
June 7, 2012
Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials
Ian M Copple, Amy E Mercer, James Firman, et al.
Scientific Reports
|
April 6, 2018
NRF2 regulates the glutamine transporter Slc38a3 (SNAT3) in kidney in response to metabolic acidosis
Adam Lister, Soline Bourgeois, Pedro H Imenez Silva, et al.
Kidney International
|
October 1, 2015
Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney
Luke M Shelton, Adam Lister, Joanne Walsh, et al.
Redox Biology
|
April 21, 2024
Biomarkers of NRF2 signalling: Current status and future challenges
Christina Morgenstern, Isabel Lastres-Becker, Birsen Can Demirdöğen, et al.
Oncotarget
|
June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget
|
February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Archives of Toxicology
|
November 15, 2018
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury
Ian M Copple, Wouter den Hollander, Giulia Callegaro, et al.
Page
of 5